Summary
Industry
Insights
Tissium, based in Paris, shows significant growth potential in the healthcare sector with its innovative biodegradable sealants and adhesives for wound closure. Unlike traditional methods such as sutures, staples, and non-biodegradable adhesives, Tissium’s products promote faster healing, fewer complications, and less invasive procedures. This approach addresses a critical need by potentially eliminating removal procedures and lowering associated risks. Supported by investors like Bpifrance and Sofinnova Partners, Tissium is well-positioned to disrupt the market with its B2B model, offering a compelling alternative to current wound care technologies.
Total Funding
$163M
- Series C (2021) $55.0M
- Series B (2019) $43.1M
- Series D (2023) $55.0M
- Debt Financing (2016) $1.5M
- Series A (2013-09-01) $8.9M
Investors
Sofinnova Partners Series C
Sofinnova Partners Series C
Bpifrance Series B
Karista Series B
Cathay Innovation Series D
Credit Mutuel Series D
Omnes Capital Series A
CM-CIC Capital Finance Series A
Full Company Profile
- Access details of the company management, and other intelligence on this company by registering for Seedtable